Insmed (INSM) Net Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Insmed (INSM) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 349.49% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -55.11% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 172.72% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 53.21% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 47.11% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -100.75% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,371.48% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -104.22% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -395.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -104.22% |
| Mar 31, 2026 | 147.35% |
| Dec 31, 2025 | 84.76% |
| Sep 30, 2025 | -20.50% |
| Jun 30, 2025 | 35.03% |
| Mar 31, 2025 | -233.57% |
| Dec 31, 2024 | 1,752.77% |
| Sep 30, 2024 | -515.29% |
| Jun 30, 2024 | 284.83% |
| Mar 31, 2024 | 208.76% |
| Dec 31, 2023 | -100.87% |
| Sep 30, 2023 | -3,783.94% |
| Jun 30, 2023 | -256.57% |
| Mar 31, 2023 | 47.48% |
| Dec 31, 2022 | 609.52% |
| Sep 30, 2022 | 95.95% |
| Jun 30, 2022 | -119.07% |
| Mar 31, 2022 | -63.01% |
| Dec 31, 2021 | -130.28% |
| Sep 30, 2021 | -52.51% |